Skip to main content
. 2022 Sep;11(9):1858–1865. doi: 10.21037/tlcr-22-225

Table 5. Subsequent treatment.

Treatment Number of pts [%]
Irinotecan 10 [34]
Nogitecan 4 [14]
CBDCA + nab-PTX 4 [14]
CBDCA + ETP 2 [7]
CDDP + Irinotecan 1 [3]
No treatment 8 [28]

pts, patients; nab-PTX, nab-paclitaxel; ETP, Etoposide; CBDCA, carboplatin; CDDP, cisplatin.